The Potential Roles and Applications of the long non-coding RNA- Interactome in glioblastoma Etiology and Treatment
Main Article Content
Christian T Stackhouse
http://orcid.org/0000-0002-6660-1963
http://orcid.org/0000-0002-6660-1963
Abstract
Long non-coding RNAs (lncRNAs) are a heterogenous population of largely evolutionary preserved transcripts, over 200nt in length which play important roles in human health and disease. These versatile and numerous transcripts can possess RNA:Protein, RNA:RNA, and RNA:DNA binding potential. Some lncRNAs also encode short peptides which can have biological significance. Many, if not a plurality of known lncRNAs, are expressed in the brain, believed to help encode complex information and facilitate various neurologic processes. In fact, lncRNA expression appears to be positively correlated with organism and organ complexity in stark contrast to coding genes. Glioblastoma (GBM) is the most common primary brain tumor with a dismal prognosis. The 5-year survival rate for GBM is around 7% with a median survival of between 14-16mos. GBM standard of care has not changed much in past decades and there is a need for new therapeutic strategies. In this review we focus on six lncRNAs of significance to cancer highlighting their potential applications in GBM treatment. These lncRNAs are MALAT1/NEAT2, HOTAIR, ZFAS1, SOX2-OT, CASC19/PCAT2, and SAMMSON. Some of these lncRNAs are well characterized across numerous cancers, but most are poorly characterized in the context of GBM or glioma. Many lncRNAs, including those highlighted herein, have been implicated in therapy resistance including chemoresistance and radiation resistance. Some of these transcripts can be found in patient serum. lncRNAs then present potential as theragnostic, prognostic, and diagnostic potential for GBM and other cancers. They may also represent therapeutic opportunities directly and as concomitant therapies to address resistance mechanisms.
Keywords:
long non-coding RNA, Interactome, Glioblastoma, MALAT1/ NEAT2, HOTAIR, ZFAS1, SOX2-OT, CASC19/PCAT2, SAMMSON
Article Details
How to Cite
STACKHOUSE, Christian T.
The Potential Roles and Applications of the long non-coding RNA- Interactome in glioblastoma Etiology and Treatment.
Medical Research Archives, [S.l.], v. 13, n. 7, july 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6804>. Date accessed: 10 nov. 2025.
doi: https://doi.org/10.18103/mra.v13i7.6804.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Taft RJ, Pheasant M, Mattick JS. 2007. "The relationship between non-protein-coding DNA and eukaryotic complexity." Bioessays 29 (3): 288-299. doi:10.1002/bies.20544.
2. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, Lagarde J, Veeravalli L, Ruan X, Ruan Y, Lassmann T, Carninci P, Brown JB, Lipovich L, Gonzalez JM, Thomas M, Davis CA, Shiekhattar R, Gingeras TR. 2012. "The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression." Genome Re 22 (9): 1775-1789. doi:10.1101/gr. 132159.111.
3. Ward M., McEwan C., Mills J.D., Janitz M. n.d. "Conservation and tissue-specific transcription patterns of long noncoding RNAs." J. Hum. Transcr. doi:10.3109/23324015.2015.1077591.
4. Murillo-Maldonado J.M., Riesgo-Escovar J.R. 2019. "The various and shared roles of lncRNAs during development." Dev. Dyn 1059-1069. doi: 10.1002/dvdy.108.
5. n.d. lncRNAdb Expert Database. https://rnacentral.org/expert-database/lncrnadb.
6. n.d. LNCipedia version 5.2. https://lncipedia.org/.
7. n.d. lncRNA Expression Database. https://ngdc.cncb.ac.cn/lncexpdb/.
8. n.d. lncRNAwiki 2.0. https://ngdc.cncb.ac.cn/lncrnawiki/.
9. n.d. LncBook. https://bio.tools/LncBook.
10. n.d. Lnc2Cancer 3.0. http://www.bio-bigdata.net/lnc2cancer.
11. Fort V, Khelifi G, Hussein SMI. 2021. "Long non-coding RNAs and transposable elements: A functional relationship." Biochim Biophys Acta Mol Cell Res. doi:10.1016/j.bbamcr.2020.118837.
12. Zottel A, Šamec N, Videtič Paska A, Jovčevska I. 2020. "Coding of Glioblastoma Progression and Therapy Resistance through Long Noncoding RNAs." 12 (7). doi:10.3390/cancers12071842.
13. Stackhouse CT, Anderson JC, Yue Z, Nguyen T, Eustace NJ, Langford CP, Wang J, Rowland JR 4th, Xing C, Mikhail FM, Cui X, Alrefai H, Bash RE, Lee KJ, Yang ES, Hjelmeland AB, Miller CR, Chen JY, Gillespie GY, Willey CD. 2022. "An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases." JCI Insight 7 (16). doi:10.1172/jci.insight.148717.
14. Luo Q., Niu H. 2022. "Progress of research on the relationship between LncRNA MALAT1 and lung diseases." J. Xinjiang Med. Univ. 45: 25–28.
15. Baspinar Y, Elmaci I, Ozpinar A, Altinoz MA. 2020. "Long non-coding RNA MALAT1 as a key target in pathogenesis of glioblastoma. Janus faces or Achilles' heal?" Gene. doi:10.1016/j.gene.2020. 144518.
16. Hutchinson J.N., Ensminger A.W., Clemson C.M., Lynch C.R., Lawrence J.B., Chess A. 2007. "A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains." BMC Genom 8. doi:10.1186/1471-2164-8-39.
17. Li Z.J., Xu C.Y., Ding B.Q., Gao M., Wei X.T., Ji N. 2017. "Long non-coding RNA MALAT1 promotes proliferation and suppresses apoptosis of glioma cells through derepressing Rap1B by sponging miR-101." Journal of Neurooncology 134: 19–28. doi:10.1007/s11060-017-2498-5.
18. Hao L, Wu W, Xu Y, Chen Y, Meng C, Yun J, Wang X. 2023. "LncRNA-MALAT1: A Key Participant in the Occurrence and Development of Cancer." Molecules 28 (5). doi:10.3390/molecules28052126.
19. Cai T., Liu Y., Xiao J. 2018. "Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma." Cancer Med 7: 1404–1415. doi:10. 1002/cam4.1384.
20. Krusnauskas R, Stakaitis R, Steponaitis G, Almstrup K, Vaitkiene P. 2023. "Identification and comparison of m6A modifications in glioblastoma non-coding RNAs with MeRIP-seq and Nanopore dRNA-seq." Epigenetics 18 (1). doi:10.1080/1559 2294.2022.2163365.
21. Xiong Z.Y., Wang L.Y., Wang Q.P., Yuan Y. 2018. "LncRNA MALAT1/miR-129 axis promotes glioma tumorigenesis by targeting SOX2." Journal of Cell Molecular Medicine 22: 3929–3940. doi:10. 1111/jcmm.13667.
22. Kocaeli AA, Aksoy SA, Ercelik M, Tezcan G, Tekin C, Kocaeli H, Bekar A, Taskapilioglu MO, Tolunay S, Tunca B. 2023. "Diabetes Mellitus-Mediated MALAT1 Expression Induces Glioblastoma Aggressiveness." Turk Neurosurg 33 (5): 821-827. doi:10.5137/1019-5149.JTN.41845-22.2.
23. Kocaeli AA, Tekin C, Ercelik M, Tezcan G, Aksoy SA, Kocaeli H, Bekar A, Taskapilioglu MO, Tolunay S, Tunca B. 2023. "Concurrent presence of diabetes affects the GLUT3 programming of glucose metabolism in glioblastoma." Eur Rev Med Pharmacol Sci 27 (17): 8110-8118. doi:10.26355/ eurrev_202309_33571.
24. Argadal OG, Mutlu M, Ak Aksoy S, Kocaeli H, Tunca B, Civan MN, Egeli U, Cecener G, Bekar A, Taskapilioglu MO, Tekin C, Tezcan G, Tolunay S. 2020. "Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas." Bosn J Basic Med Sci 20 (1): 63-69. doi:10.17305/bjbms.2019.4297.
25. Ak Aksoy S, Mutlu M, Tunca B, Kocaeli H, Taskapilioglu MO, Bekar A, Tekin C, Argadal OG, Civan MN, Kaya İS, Ocak PE, Tolunay S. 2021. "Coexistence of TERT C228T mutation and MALAT1 dysregulation in primary glioblastoma: new prognostic and therapeutic targets." Neurol Res 43 (11): 916-925. doi:10.1080/01616412.2021. 1948738.
26. Witusik-Perkowska M, Jaskólski DJ, Liberski PP, Szemraj J. 2022. "If Artificial In Vitro Microenvironment Can Influence Tumor Drug Resistance Network via Modulation of lncRNA Expression?-Comparative Analysis of Glioblastoma-Derived Cell Culture Models and Initial Tumors In Vivo." Cell Mol Neurobiol 42 (4): 1005-1020. doi:10.1007/s10571-020-00991-3.
27. Chen W., Xu X.K., Li J.L., Kong K.K., Li H., Chen C., He J., Wang F., Li P., Ge X.S. 2017. "MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression." Oncotarget 8: 22783–22799. doi:10.18632/oncota rget.15199.
28. Li H., Yuan X., Yan D., Li D., Guan F., Dong Y., Wang H., Liu X., Yang B. 2017. "Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide." Cell Physiol. Biochem 42: 1192–1201. doi:10.1159/000478917.
29. Hazra R, Utama R, Naik P, Dobin A, Spector DL. 2023. "Identification of glioblastoma stem cell-associated lncRNAs using single-cell RNA-sequencing datasets." bioRxiv. doi:10.1101/2023. 01.20.524887.
30. Mazur DV, Mishanova AV, Kovalenko TF, Shakhparonov MI, Antipova NV. 2023. "Influence of the Cultivation Conditions of the Glioblastoma Neurosphere on the Expression of MALAT1 and LINCROR Long Non-coding RNA Genes." Biochem Biophys 508 (1): 21-24. doi:10.1134/ S1607672922700053.
31. Vazifehmand R, Ali DS, Othman Z, Chau DM, Stanslas J, Shafa M, Sekawi Z. 2022. "The evaluation expression of non-coding RNAs in response to HSV-G47∆ oncolytic virus infection in glioblastoma multiforme cancer stem cells." J Neurovirol 28 (4-6): 566-582. doi:10.1007/s13365-022-01089-w.
32. Zhang Y., Zhang K., Luo Z., Liu L., Wu L., Liu J. 2016. "Circulating long non-coding HOX transcript antisense intergenic ribonucleic acid in plasma as a potential biomarker for diagnosis of breast cancer." Thorac. Cancer 7: 627–632. doi:10.1111/ 1759-7714.12373.
33. Tsai M.C., Manor O., Wan Y., Mosammaparast N., Wang J.K., Lan F., Shi Y., Segal E., Chang H.Y. 2010. "Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes." Science 329: 689–693. doi:10.1126/science.1192002.
34. Wang X, Yu X, Xu H, Wei K, Wang S, Wang Y, Han J. 2022. "Serum-derived extracellular vesicles facilitate temozolomide resistance in glioblastoma through a HOTAIR-dependent mechanism." Cell Death Dis 13 (4). doi:10.1038/s41419-022-04699-8.
35. Guo S, King P, Liang E, Guo AA, Liu M. 2022. "LncRNA HOTAIR sponges miR-301a-3p to promote glioblastoma proliferation and invasion through upregulating FOSL1." Cell Signal. doi:10. 1016/j.cellsig.2022.110306.
36. Rahmani F, Mohammed Al-Asady A, Hanaie R, Zandigohar M, Faridnejad H, Payazdan M, Safavi P, Ryzhikov M, Hassanian SM. 2023. "Interplay between lncRNA/miRNA and Wnt/ß-catenin signaling in brain cancer tumorigenesis." Excli Journal 1211-1222. doi:10.17179/excli2023-6490.
37. Zhang J, Li N, Fu J, Zhou W. 2020. "Long noncoding RNA HOTAIR promotes medulloblastoma growth, migration and invasion by sponging miR-1/miR-206 and targeting YY1." Biomed Pharmacother. doi:10.1016/j.biopha.2020.109887.
38. Zhang J.-X., Han L., Bao Z.-S., Wang Y.-Y., Chen L.-Y., Yan W., Yu S.-Z., Pu P.-Y., Liu N., You Y.-P. 2017. "HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma." Neuro-Oncology 15: 1595. doi:10.1093/neuonc/nox190.
39. Zhao W.H., Yuan H.Y., Ren X.Y., Huang K., Guo Z.Y. 2019. "Association between expression of HOTAIR and invasiveness of gliomas, and its predictive value." Adv. Clin. Exp. Med 28: 1179–1183. doi:10.17219/acem/99527.
40. Yang E, Hong B, Wang Y, Wang Q, Zhao J, Cui X, Wu Y, Yang S, Su D, Liu X, Kang C. 2024. "EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma." Cancer Lett. doi:10.1016 /j.canlet.2024.216812.
41. Zhao J, Jin W, Yi K, Wang Q, Zhou J, Tan Y, Xu C, Xiao M, Hong B, Xu F, Zhang K, Kang C. 2021. "Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells." Pharmacol Res. doi:10.1016 /j.phrs.2021.105764.
42. Li P, Yang Y, Luan C, Wang W, Jiang Y, Zhao Z, Wang B, Zhao Y, Bai Y, Liu M, Zhao Z, Zhang L, Qian Y, Shi J. 2025. "A HOTAIR-associated super-enhancer orchestrates glioblastoma malignancy via MEST." Oncogenesis 14 (1). doi:10.1038/s41389-025-00551-8.
43. Yuan Z, Yang Z, Li W, Wu A, Su Z, Jiang B. 2020. "Exosome-Mediated Transfer of Long Noncoding RNA HOTAIR Regulates Temozolomide Resistance by miR-519a-3p/RRM1 Axis in Glioblastoma." Cancer Biother Radiopharm. doi:10.1089/cbr. 2019.3499.
44. Zhou X, Ren Y, Zhang J, Zhang C, Zhang K, Han L. 2015. "HOTAIR is a therapeutic target in glioblastoma." Oncotarget 6 (10): 8353–8365. doi:10.18632/oncotarget.3229.
45. Wang Y, Yi K, Liu X, Tan Y, Jin W, Li Y, Zhou J, Wang H, Kang C. 2021. "HOTAIR Up-Regulation Activates NF-κB to Induce Immunoescape in Gliomas." Front Immunol. doi:10.3389/fimmu. 2021.785463.
46. Zhu W, Zhao H, Xu F, Huang B, Dai X, Sun J, Nyalali AMK, Zhang K, Ni S. 2021. "The lipid-lowering drug fenofibrate combined with si-HOTAIR can effectively inhibit the proliferation of gliomas." BMC Cancer 21 (1). doi:10.1186/s12885-021-08417-z.
47. Ghafouri-Fard S, Kamali MJ, Abak A, Shoorei H, Taheri M. 2021. "LncRNA ZFAS1: Role in tumorigenesis and other diseases." Biomed Pharmacother. doi:10.1016/j.biopha.2021.111999.
48. Z. Guo, Y. Meng, C. Xie, N. Zhao, M. Li, X. Zhai, C. Zhou, K. Li, T. Liu, X. Yang. 2019. "Translated long non-coding ribonucleic acid ZFAS1 promotes cancer cell migration by elevating reactive oxygen species production in Hepatocellular carcinoma." Fronteirs in Genetics 10: 1111. doi:10.3389/fgene.2019.01111.
49. Lv Q.L., Chen S.H., Zhang X., Sun B., Hu L., Qu Q., Huang Y.T., Wang G.H., Liu Y.L., Zhang Y.Y. 2017. "Upregulation of long noncoding RNA zinc finger antisense 1 enhances epithelial-mesenchymal transition in vitro and predicts poor prognosis in glioma." Tumour Biol. doi:10.1177 /1010428317695022.
50. B. Zhang, J. Chen, M. Cui, Y. Jiang. 2020. "LncRNA ZFAS1/miR-1271-5p/HK2 promotes glioma development through regulating proliferation, migration, invasion and apoptosis." Neurochem. Res. 45 (12): 2828-2839. doi:10.1007/s11064-020-03131-x.
51. Steponaitis G, Dragunaite R, Stakaitis R, Sharma A, Tamasauskas A, Skiriute D. 2025. "m6A-lncRNA landscape highlights reduced levels of m6A modification in glioblastoma as compared to low-grade gliom." Mol Med 31 (1). doi:10.1186 /s10020-025-01254-x.
52. Feng Y, Xu Y, Gao Y, Chen Y, Wang X, Chen Z. 2021. "A novel lncRNA SOX2OT promotes the malignancy of human colorectal cancer by interacting with miR-194-5p/SOX5 axis." Cell Death Dis 12 (5): 499. doi:10.1038/s41419-021-03756-y.
53. Dodangeh F, Sadeghi Z, Maleki P, Raheb J. 2023. "Long non-coding RNA SOX2-OT enhances cancer biological traits via sponging to tumor suppressor miR-122-3p and miR-194-5p in non-small cell lung carcinoma." Sci Rep 13 (1). doi:10.1038/s41598-023-39000-0.
54. Chen Z, Xu S, Zhang Q. 2021. "LncRNA SOX2-OT/miR-30d-5p/PDK1 Regulates PD-L1 Checkpoint Through the mTOR Signaling Pathway to Promote Non-small Cell Lung Cancer Progression and Immune Escape." Front Genet. doi:10.3389/fgene. 2021.674856.
55. Dong H, Zeng L, Chen W, Zhang Q, Wang F, Wu Y, Cui B, Qi J, Zhang X, Liu C, Deng J, Yu Y, Schmitt CA, Du J. 2023. "N6-methyladenine-mediated aberrant activation of the lncRNA SOX2OT-GLI1 loop promotes non-small-cell lung cancer stemness." Cell Death Discov 9 (1). doi:10. 1038/s41420-023-01442-w.
56. Haghi B, Saghaeian Jazi M, Khosravi A, Jafari SM, Asadi J. 2022. "SOX2OT lncRNA Inhibition Suppresses the Stemness Characteristics of Esophageal Tumorspheres." Noncoding RNA 8 (6). doi:10.3390/ncrna8060080.
57. Chang X, Zhang H, Yang Q, Pang L. 2020. "LncRNA SOX2OT affects cervical cancer cell growth, migration and invasion by regulating SOX2." Cell Cycle 19 (11): 1391-1403. doi:10.1080 /15384101.2020.1750812.
58. Wang H, Hu Q, Tong Y, Li S, Chen M, Wang B, Li H. 2021. "LncRNA SOX2-OT regulates miR-192-5p/RAB2A axis and ERK pathway to promote glioblastoma cell growth." Cell Cycle 2010-2020. doi:10.1080/15384101.2021.1965722.
59. Fouani Y, Gholipour A, Oveisee M, Shahryari A, Saberi H, Mowla SJ, Malakootian M. 2023. "Distinct gene expression patterns of SOX2 and SOX2OT variants in different types of brain tumours." J Genet 102 (25): PMID 37017197.
60. Shahryari A, Rafiee MR, Fouani Y, Oliae NA, Samaei NM, Shafiee M, Semnani S, Vasei M, Mowla SJ. 2014. "Two novel splice variants of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are coupregulated with SOX2 and OCT4 in esophageal squamous cell carcinoma." Stem Cells 32 (1): 126-134. doi:10.100 2/stem.1542.
61. Liu B, Zhou J, Wang C, Chi Y, Wei Q, Fu Z, Lian C, Huang Q, Liao C, Yang Z, Zeng H, Xu N, Guo H. 2020. "LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma." Cell Death Dis 11 (5). doi:10.1038 /s41419-020-2540-y.
62. Wu Y, Mou J, Zhou G, Yuan C. 2024. "CASC19: An Oncogenic Long Non-coding RNA in Different Cancers." Curr Pharm Des 30 (15): 1157-1166. doi:10.2174/0113816128300061240319034243.
63. Liu H, Zheng W, Chen Q, Zhou Y, Pan Y, Zhang J, Bai Y, Shao C. 2021. "lncRNA CASC19 Contributes to Radioresistance of Nasopharyngeal Carcinoma by Promoting Autophagy via AMPK-mTOR Pathway." Int J Mol Sci 22 (3). doi:10. 3390/ijms22031407.
64. Liu H, Chen Q, Zheng W, Zhou Y, Bai Y, Pan Y, Zhang J, Shao C. 2023. "LncRNA CASC19 Enhances the Radioresistance of Nasopharyngeal Carcinoma by Regulating the miR-340-3p/FKBP5 Axis." Int J Mol Sci 24 (3). doi:10.3390/ijms24033047.
65. Song J, Zhang S, Sun Y, Gu J, Ye Z, Sun X, Tang Q. 2021. "A Radioresponse-Related lncRNA Biomarker Signature for Risk Classification and Prognosis Prediction in Non-Small-Cell Lung Cancer." J Oncol. doi:10.1155/2021/4338838.
66. Mohapatra S, Winkle M, Ton AN, Nguyen D, Calin GA. 2023. "The Role of Non-Coding RNAs in Chromosomal Instability in Cancer." J Pharmacol Exp Ther 384 (1): 10-19. doi:10.1124/jpet.122.001357.
67. Wu YJ, Yang QS, Chen H, Wang JT, Wang WB, Zhou L. 2021. "Long non coding RNA CASC19 promotes glioma progression by modulating the miR 454 3p/RAB5A axis and is associated with unfavorable MRI features." Oncol Rep 45 (2): 728-737. doi:10.3892/or.2020.7876.
68. Zheng X, Tian X, Zhang Q, Shi P, Li S. 2020. "Long non-coding RNA SAMMSON as a novel potential diagnostic and prognostic biomarker for oral squamous cell carcinoma." J Dent Sci 15 (3): 329-335. doi:10.1016/j.jds.2019.11.008.
69. Ghasemian M, Babaahmadi-Rezaei H, Khedri A, Selvaraj C. 2023. "The oncogenic role of SAMMSON lncRNA in tumorigenesis: A comprehensive review with especial focus on melanoma." J Cell Mol Med 27 (24): 3966-3973. doi:10.1111/jcmm.17978.
70. Han S, Yan Y, Ren Y, Hu Y, Wang Y, Chen L, Zhi Z, Zheng Y, Shao Y, Liu J. 2021. "LncRNA SAMMSON Mediates Adaptive Resistance to RAF Inhibition in BRAF-Mutant Melanoma Cells." Cancer Res 81 (11): 2918-2929. doi:10.1158/0008-5472.CAN-20-3145.
71. Dewaele S, Delhaye L, De Paepe B, de Bony EJ, De Wilde J, Vanderheyden K, Anckaert J, Yigit N, Nuytens J, Vanden Eynde E, Smet J, Verschoore M, Nemati F, Decaudin D, Rodrigues M, Zhao P, Jochemsen A, Leucci E, Vandesompele J, Van Dorpe J, Marine JC, Van C. 2022. "The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival." Oncogene 41 (1): 15-25. doi:10.1038/s41388-021-02006-x.
72. Orre C, Dieu X, Guillon J, Gueguen N, Ahmadpour ST, Dumas JF, Khiati S, Reynier P, Lenaers G, Coqueret O, Chevrollier A, Mirebeau-Prunier D, Desquiret-Dumas V. 2021. "The Long Non-Coding RNA SAMMSON Is a Regulator of Chemosensitivity and Metabolic Orientation in MCF-7 Doxorubicin-Resistant Breast Cancer Cells." Biology (Basel) 10 (11): 1156. doi:10.3390/ biology10111156.
73. Ni H, Wang K, Xie P, Zuo J, Liu W, Liu C. 2021. "LncRNA SAMMSON Knockdown Inhibits the Malignancy of Glioblastoma Cells by Inactivation of the PI3K/Akt Pathway." Cell Mol Neurobiol 41 (1): 79-90. doi:10.1007/s10571-020-00833-2.
74. Xie J, Wang X, Liu S, Chen C, Jiang F, Mao K, Zeng F. 2019. "LncRNA SAMMSON overexpression distinguished glioblastoma patients from patients with diffuse neurosarcoidosis." Neuroreport 30 (12): 817-821. doi:10.1097/WNR.0000000000001278.
2. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, Lagarde J, Veeravalli L, Ruan X, Ruan Y, Lassmann T, Carninci P, Brown JB, Lipovich L, Gonzalez JM, Thomas M, Davis CA, Shiekhattar R, Gingeras TR. 2012. "The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression." Genome Re 22 (9): 1775-1789. doi:10.1101/gr. 132159.111.
3. Ward M., McEwan C., Mills J.D., Janitz M. n.d. "Conservation and tissue-specific transcription patterns of long noncoding RNAs." J. Hum. Transcr. doi:10.3109/23324015.2015.1077591.
4. Murillo-Maldonado J.M., Riesgo-Escovar J.R. 2019. "The various and shared roles of lncRNAs during development." Dev. Dyn 1059-1069. doi: 10.1002/dvdy.108.
5. n.d. lncRNAdb Expert Database. https://rnacentral.org/expert-database/lncrnadb.
6. n.d. LNCipedia version 5.2. https://lncipedia.org/.
7. n.d. lncRNA Expression Database. https://ngdc.cncb.ac.cn/lncexpdb/.
8. n.d. lncRNAwiki 2.0. https://ngdc.cncb.ac.cn/lncrnawiki/.
9. n.d. LncBook. https://bio.tools/LncBook.
10. n.d. Lnc2Cancer 3.0. http://www.bio-bigdata.net/lnc2cancer.
11. Fort V, Khelifi G, Hussein SMI. 2021. "Long non-coding RNAs and transposable elements: A functional relationship." Biochim Biophys Acta Mol Cell Res. doi:10.1016/j.bbamcr.2020.118837.
12. Zottel A, Šamec N, Videtič Paska A, Jovčevska I. 2020. "Coding of Glioblastoma Progression and Therapy Resistance through Long Noncoding RNAs." 12 (7). doi:10.3390/cancers12071842.
13. Stackhouse CT, Anderson JC, Yue Z, Nguyen T, Eustace NJ, Langford CP, Wang J, Rowland JR 4th, Xing C, Mikhail FM, Cui X, Alrefai H, Bash RE, Lee KJ, Yang ES, Hjelmeland AB, Miller CR, Chen JY, Gillespie GY, Willey CD. 2022. "An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases." JCI Insight 7 (16). doi:10.1172/jci.insight.148717.
14. Luo Q., Niu H. 2022. "Progress of research on the relationship between LncRNA MALAT1 and lung diseases." J. Xinjiang Med. Univ. 45: 25–28.
15. Baspinar Y, Elmaci I, Ozpinar A, Altinoz MA. 2020. "Long non-coding RNA MALAT1 as a key target in pathogenesis of glioblastoma. Janus faces or Achilles' heal?" Gene. doi:10.1016/j.gene.2020. 144518.
16. Hutchinson J.N., Ensminger A.W., Clemson C.M., Lynch C.R., Lawrence J.B., Chess A. 2007. "A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains." BMC Genom 8. doi:10.1186/1471-2164-8-39.
17. Li Z.J., Xu C.Y., Ding B.Q., Gao M., Wei X.T., Ji N. 2017. "Long non-coding RNA MALAT1 promotes proliferation and suppresses apoptosis of glioma cells through derepressing Rap1B by sponging miR-101." Journal of Neurooncology 134: 19–28. doi:10.1007/s11060-017-2498-5.
18. Hao L, Wu W, Xu Y, Chen Y, Meng C, Yun J, Wang X. 2023. "LncRNA-MALAT1: A Key Participant in the Occurrence and Development of Cancer." Molecules 28 (5). doi:10.3390/molecules28052126.
19. Cai T., Liu Y., Xiao J. 2018. "Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma." Cancer Med 7: 1404–1415. doi:10. 1002/cam4.1384.
20. Krusnauskas R, Stakaitis R, Steponaitis G, Almstrup K, Vaitkiene P. 2023. "Identification and comparison of m6A modifications in glioblastoma non-coding RNAs with MeRIP-seq and Nanopore dRNA-seq." Epigenetics 18 (1). doi:10.1080/1559 2294.2022.2163365.
21. Xiong Z.Y., Wang L.Y., Wang Q.P., Yuan Y. 2018. "LncRNA MALAT1/miR-129 axis promotes glioma tumorigenesis by targeting SOX2." Journal of Cell Molecular Medicine 22: 3929–3940. doi:10. 1111/jcmm.13667.
22. Kocaeli AA, Aksoy SA, Ercelik M, Tezcan G, Tekin C, Kocaeli H, Bekar A, Taskapilioglu MO, Tolunay S, Tunca B. 2023. "Diabetes Mellitus-Mediated MALAT1 Expression Induces Glioblastoma Aggressiveness." Turk Neurosurg 33 (5): 821-827. doi:10.5137/1019-5149.JTN.41845-22.2.
23. Kocaeli AA, Tekin C, Ercelik M, Tezcan G, Aksoy SA, Kocaeli H, Bekar A, Taskapilioglu MO, Tolunay S, Tunca B. 2023. "Concurrent presence of diabetes affects the GLUT3 programming of glucose metabolism in glioblastoma." Eur Rev Med Pharmacol Sci 27 (17): 8110-8118. doi:10.26355/ eurrev_202309_33571.
24. Argadal OG, Mutlu M, Ak Aksoy S, Kocaeli H, Tunca B, Civan MN, Egeli U, Cecener G, Bekar A, Taskapilioglu MO, Tekin C, Tezcan G, Tolunay S. 2020. "Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas." Bosn J Basic Med Sci 20 (1): 63-69. doi:10.17305/bjbms.2019.4297.
25. Ak Aksoy S, Mutlu M, Tunca B, Kocaeli H, Taskapilioglu MO, Bekar A, Tekin C, Argadal OG, Civan MN, Kaya İS, Ocak PE, Tolunay S. 2021. "Coexistence of TERT C228T mutation and MALAT1 dysregulation in primary glioblastoma: new prognostic and therapeutic targets." Neurol Res 43 (11): 916-925. doi:10.1080/01616412.2021. 1948738.
26. Witusik-Perkowska M, Jaskólski DJ, Liberski PP, Szemraj J. 2022. "If Artificial In Vitro Microenvironment Can Influence Tumor Drug Resistance Network via Modulation of lncRNA Expression?-Comparative Analysis of Glioblastoma-Derived Cell Culture Models and Initial Tumors In Vivo." Cell Mol Neurobiol 42 (4): 1005-1020. doi:10.1007/s10571-020-00991-3.
27. Chen W., Xu X.K., Li J.L., Kong K.K., Li H., Chen C., He J., Wang F., Li P., Ge X.S. 2017. "MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression." Oncotarget 8: 22783–22799. doi:10.18632/oncota rget.15199.
28. Li H., Yuan X., Yan D., Li D., Guan F., Dong Y., Wang H., Liu X., Yang B. 2017. "Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide." Cell Physiol. Biochem 42: 1192–1201. doi:10.1159/000478917.
29. Hazra R, Utama R, Naik P, Dobin A, Spector DL. 2023. "Identification of glioblastoma stem cell-associated lncRNAs using single-cell RNA-sequencing datasets." bioRxiv. doi:10.1101/2023. 01.20.524887.
30. Mazur DV, Mishanova AV, Kovalenko TF, Shakhparonov MI, Antipova NV. 2023. "Influence of the Cultivation Conditions of the Glioblastoma Neurosphere on the Expression of MALAT1 and LINCROR Long Non-coding RNA Genes." Biochem Biophys 508 (1): 21-24. doi:10.1134/ S1607672922700053.
31. Vazifehmand R, Ali DS, Othman Z, Chau DM, Stanslas J, Shafa M, Sekawi Z. 2022. "The evaluation expression of non-coding RNAs in response to HSV-G47∆ oncolytic virus infection in glioblastoma multiforme cancer stem cells." J Neurovirol 28 (4-6): 566-582. doi:10.1007/s13365-022-01089-w.
32. Zhang Y., Zhang K., Luo Z., Liu L., Wu L., Liu J. 2016. "Circulating long non-coding HOX transcript antisense intergenic ribonucleic acid in plasma as a potential biomarker for diagnosis of breast cancer." Thorac. Cancer 7: 627–632. doi:10.1111/ 1759-7714.12373.
33. Tsai M.C., Manor O., Wan Y., Mosammaparast N., Wang J.K., Lan F., Shi Y., Segal E., Chang H.Y. 2010. "Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes." Science 329: 689–693. doi:10.1126/science.1192002.
34. Wang X, Yu X, Xu H, Wei K, Wang S, Wang Y, Han J. 2022. "Serum-derived extracellular vesicles facilitate temozolomide resistance in glioblastoma through a HOTAIR-dependent mechanism." Cell Death Dis 13 (4). doi:10.1038/s41419-022-04699-8.
35. Guo S, King P, Liang E, Guo AA, Liu M. 2022. "LncRNA HOTAIR sponges miR-301a-3p to promote glioblastoma proliferation and invasion through upregulating FOSL1." Cell Signal. doi:10. 1016/j.cellsig.2022.110306.
36. Rahmani F, Mohammed Al-Asady A, Hanaie R, Zandigohar M, Faridnejad H, Payazdan M, Safavi P, Ryzhikov M, Hassanian SM. 2023. "Interplay between lncRNA/miRNA and Wnt/ß-catenin signaling in brain cancer tumorigenesis." Excli Journal 1211-1222. doi:10.17179/excli2023-6490.
37. Zhang J, Li N, Fu J, Zhou W. 2020. "Long noncoding RNA HOTAIR promotes medulloblastoma growth, migration and invasion by sponging miR-1/miR-206 and targeting YY1." Biomed Pharmacother. doi:10.1016/j.biopha.2020.109887.
38. Zhang J.-X., Han L., Bao Z.-S., Wang Y.-Y., Chen L.-Y., Yan W., Yu S.-Z., Pu P.-Y., Liu N., You Y.-P. 2017. "HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma." Neuro-Oncology 15: 1595. doi:10.1093/neuonc/nox190.
39. Zhao W.H., Yuan H.Y., Ren X.Y., Huang K., Guo Z.Y. 2019. "Association between expression of HOTAIR and invasiveness of gliomas, and its predictive value." Adv. Clin. Exp. Med 28: 1179–1183. doi:10.17219/acem/99527.
40. Yang E, Hong B, Wang Y, Wang Q, Zhao J, Cui X, Wu Y, Yang S, Su D, Liu X, Kang C. 2024. "EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma." Cancer Lett. doi:10.1016 /j.canlet.2024.216812.
41. Zhao J, Jin W, Yi K, Wang Q, Zhou J, Tan Y, Xu C, Xiao M, Hong B, Xu F, Zhang K, Kang C. 2021. "Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells." Pharmacol Res. doi:10.1016 /j.phrs.2021.105764.
42. Li P, Yang Y, Luan C, Wang W, Jiang Y, Zhao Z, Wang B, Zhao Y, Bai Y, Liu M, Zhao Z, Zhang L, Qian Y, Shi J. 2025. "A HOTAIR-associated super-enhancer orchestrates glioblastoma malignancy via MEST." Oncogenesis 14 (1). doi:10.1038/s41389-025-00551-8.
43. Yuan Z, Yang Z, Li W, Wu A, Su Z, Jiang B. 2020. "Exosome-Mediated Transfer of Long Noncoding RNA HOTAIR Regulates Temozolomide Resistance by miR-519a-3p/RRM1 Axis in Glioblastoma." Cancer Biother Radiopharm. doi:10.1089/cbr. 2019.3499.
44. Zhou X, Ren Y, Zhang J, Zhang C, Zhang K, Han L. 2015. "HOTAIR is a therapeutic target in glioblastoma." Oncotarget 6 (10): 8353–8365. doi:10.18632/oncotarget.3229.
45. Wang Y, Yi K, Liu X, Tan Y, Jin W, Li Y, Zhou J, Wang H, Kang C. 2021. "HOTAIR Up-Regulation Activates NF-κB to Induce Immunoescape in Gliomas." Front Immunol. doi:10.3389/fimmu. 2021.785463.
46. Zhu W, Zhao H, Xu F, Huang B, Dai X, Sun J, Nyalali AMK, Zhang K, Ni S. 2021. "The lipid-lowering drug fenofibrate combined with si-HOTAIR can effectively inhibit the proliferation of gliomas." BMC Cancer 21 (1). doi:10.1186/s12885-021-08417-z.
47. Ghafouri-Fard S, Kamali MJ, Abak A, Shoorei H, Taheri M. 2021. "LncRNA ZFAS1: Role in tumorigenesis and other diseases." Biomed Pharmacother. doi:10.1016/j.biopha.2021.111999.
48. Z. Guo, Y. Meng, C. Xie, N. Zhao, M. Li, X. Zhai, C. Zhou, K. Li, T. Liu, X. Yang. 2019. "Translated long non-coding ribonucleic acid ZFAS1 promotes cancer cell migration by elevating reactive oxygen species production in Hepatocellular carcinoma." Fronteirs in Genetics 10: 1111. doi:10.3389/fgene.2019.01111.
49. Lv Q.L., Chen S.H., Zhang X., Sun B., Hu L., Qu Q., Huang Y.T., Wang G.H., Liu Y.L., Zhang Y.Y. 2017. "Upregulation of long noncoding RNA zinc finger antisense 1 enhances epithelial-mesenchymal transition in vitro and predicts poor prognosis in glioma." Tumour Biol. doi:10.1177 /1010428317695022.
50. B. Zhang, J. Chen, M. Cui, Y. Jiang. 2020. "LncRNA ZFAS1/miR-1271-5p/HK2 promotes glioma development through regulating proliferation, migration, invasion and apoptosis." Neurochem. Res. 45 (12): 2828-2839. doi:10.1007/s11064-020-03131-x.
51. Steponaitis G, Dragunaite R, Stakaitis R, Sharma A, Tamasauskas A, Skiriute D. 2025. "m6A-lncRNA landscape highlights reduced levels of m6A modification in glioblastoma as compared to low-grade gliom." Mol Med 31 (1). doi:10.1186 /s10020-025-01254-x.
52. Feng Y, Xu Y, Gao Y, Chen Y, Wang X, Chen Z. 2021. "A novel lncRNA SOX2OT promotes the malignancy of human colorectal cancer by interacting with miR-194-5p/SOX5 axis." Cell Death Dis 12 (5): 499. doi:10.1038/s41419-021-03756-y.
53. Dodangeh F, Sadeghi Z, Maleki P, Raheb J. 2023. "Long non-coding RNA SOX2-OT enhances cancer biological traits via sponging to tumor suppressor miR-122-3p and miR-194-5p in non-small cell lung carcinoma." Sci Rep 13 (1). doi:10.1038/s41598-023-39000-0.
54. Chen Z, Xu S, Zhang Q. 2021. "LncRNA SOX2-OT/miR-30d-5p/PDK1 Regulates PD-L1 Checkpoint Through the mTOR Signaling Pathway to Promote Non-small Cell Lung Cancer Progression and Immune Escape." Front Genet. doi:10.3389/fgene. 2021.674856.
55. Dong H, Zeng L, Chen W, Zhang Q, Wang F, Wu Y, Cui B, Qi J, Zhang X, Liu C, Deng J, Yu Y, Schmitt CA, Du J. 2023. "N6-methyladenine-mediated aberrant activation of the lncRNA SOX2OT-GLI1 loop promotes non-small-cell lung cancer stemness." Cell Death Discov 9 (1). doi:10. 1038/s41420-023-01442-w.
56. Haghi B, Saghaeian Jazi M, Khosravi A, Jafari SM, Asadi J. 2022. "SOX2OT lncRNA Inhibition Suppresses the Stemness Characteristics of Esophageal Tumorspheres." Noncoding RNA 8 (6). doi:10.3390/ncrna8060080.
57. Chang X, Zhang H, Yang Q, Pang L. 2020. "LncRNA SOX2OT affects cervical cancer cell growth, migration and invasion by regulating SOX2." Cell Cycle 19 (11): 1391-1403. doi:10.1080 /15384101.2020.1750812.
58. Wang H, Hu Q, Tong Y, Li S, Chen M, Wang B, Li H. 2021. "LncRNA SOX2-OT regulates miR-192-5p/RAB2A axis and ERK pathway to promote glioblastoma cell growth." Cell Cycle 2010-2020. doi:10.1080/15384101.2021.1965722.
59. Fouani Y, Gholipour A, Oveisee M, Shahryari A, Saberi H, Mowla SJ, Malakootian M. 2023. "Distinct gene expression patterns of SOX2 and SOX2OT variants in different types of brain tumours." J Genet 102 (25): PMID 37017197.
60. Shahryari A, Rafiee MR, Fouani Y, Oliae NA, Samaei NM, Shafiee M, Semnani S, Vasei M, Mowla SJ. 2014. "Two novel splice variants of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are coupregulated with SOX2 and OCT4 in esophageal squamous cell carcinoma." Stem Cells 32 (1): 126-134. doi:10.100 2/stem.1542.
61. Liu B, Zhou J, Wang C, Chi Y, Wei Q, Fu Z, Lian C, Huang Q, Liao C, Yang Z, Zeng H, Xu N, Guo H. 2020. "LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma." Cell Death Dis 11 (5). doi:10.1038 /s41419-020-2540-y.
62. Wu Y, Mou J, Zhou G, Yuan C. 2024. "CASC19: An Oncogenic Long Non-coding RNA in Different Cancers." Curr Pharm Des 30 (15): 1157-1166. doi:10.2174/0113816128300061240319034243.
63. Liu H, Zheng W, Chen Q, Zhou Y, Pan Y, Zhang J, Bai Y, Shao C. 2021. "lncRNA CASC19 Contributes to Radioresistance of Nasopharyngeal Carcinoma by Promoting Autophagy via AMPK-mTOR Pathway." Int J Mol Sci 22 (3). doi:10. 3390/ijms22031407.
64. Liu H, Chen Q, Zheng W, Zhou Y, Bai Y, Pan Y, Zhang J, Shao C. 2023. "LncRNA CASC19 Enhances the Radioresistance of Nasopharyngeal Carcinoma by Regulating the miR-340-3p/FKBP5 Axis." Int J Mol Sci 24 (3). doi:10.3390/ijms24033047.
65. Song J, Zhang S, Sun Y, Gu J, Ye Z, Sun X, Tang Q. 2021. "A Radioresponse-Related lncRNA Biomarker Signature for Risk Classification and Prognosis Prediction in Non-Small-Cell Lung Cancer." J Oncol. doi:10.1155/2021/4338838.
66. Mohapatra S, Winkle M, Ton AN, Nguyen D, Calin GA. 2023. "The Role of Non-Coding RNAs in Chromosomal Instability in Cancer." J Pharmacol Exp Ther 384 (1): 10-19. doi:10.1124/jpet.122.001357.
67. Wu YJ, Yang QS, Chen H, Wang JT, Wang WB, Zhou L. 2021. "Long non coding RNA CASC19 promotes glioma progression by modulating the miR 454 3p/RAB5A axis and is associated with unfavorable MRI features." Oncol Rep 45 (2): 728-737. doi:10.3892/or.2020.7876.
68. Zheng X, Tian X, Zhang Q, Shi P, Li S. 2020. "Long non-coding RNA SAMMSON as a novel potential diagnostic and prognostic biomarker for oral squamous cell carcinoma." J Dent Sci 15 (3): 329-335. doi:10.1016/j.jds.2019.11.008.
69. Ghasemian M, Babaahmadi-Rezaei H, Khedri A, Selvaraj C. 2023. "The oncogenic role of SAMMSON lncRNA in tumorigenesis: A comprehensive review with especial focus on melanoma." J Cell Mol Med 27 (24): 3966-3973. doi:10.1111/jcmm.17978.
70. Han S, Yan Y, Ren Y, Hu Y, Wang Y, Chen L, Zhi Z, Zheng Y, Shao Y, Liu J. 2021. "LncRNA SAMMSON Mediates Adaptive Resistance to RAF Inhibition in BRAF-Mutant Melanoma Cells." Cancer Res 81 (11): 2918-2929. doi:10.1158/0008-5472.CAN-20-3145.
71. Dewaele S, Delhaye L, De Paepe B, de Bony EJ, De Wilde J, Vanderheyden K, Anckaert J, Yigit N, Nuytens J, Vanden Eynde E, Smet J, Verschoore M, Nemati F, Decaudin D, Rodrigues M, Zhao P, Jochemsen A, Leucci E, Vandesompele J, Van Dorpe J, Marine JC, Van C. 2022. "The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival." Oncogene 41 (1): 15-25. doi:10.1038/s41388-021-02006-x.
72. Orre C, Dieu X, Guillon J, Gueguen N, Ahmadpour ST, Dumas JF, Khiati S, Reynier P, Lenaers G, Coqueret O, Chevrollier A, Mirebeau-Prunier D, Desquiret-Dumas V. 2021. "The Long Non-Coding RNA SAMMSON Is a Regulator of Chemosensitivity and Metabolic Orientation in MCF-7 Doxorubicin-Resistant Breast Cancer Cells." Biology (Basel) 10 (11): 1156. doi:10.3390/ biology10111156.
73. Ni H, Wang K, Xie P, Zuo J, Liu W, Liu C. 2021. "LncRNA SAMMSON Knockdown Inhibits the Malignancy of Glioblastoma Cells by Inactivation of the PI3K/Akt Pathway." Cell Mol Neurobiol 41 (1): 79-90. doi:10.1007/s10571-020-00833-2.
74. Xie J, Wang X, Liu S, Chen C, Jiang F, Mao K, Zeng F. 2019. "LncRNA SAMMSON overexpression distinguished glioblastoma patients from patients with diffuse neurosarcoidosis." Neuroreport 30 (12): 817-821. doi:10.1097/WNR.0000000000001278.